Researchers from the University of Central Florida recently received a $400,000 grant from the Juvenile Diabetes Research Foundation, which they will use to create a tube that resists infection and encapsulation and is inserted under the skin for the delivery of insulin via a pump.
Featured
Industry News NOVARTIS CORPORATION: Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis
Latest News
Federal Issues
AQUESTIVE THERAPEUTICS: Granted Temporary Restraining Order (TRO) Against Alvogen
- PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION: PCMA Supports Legislation to Ensure Patients Pay Lowest Price for Prescription Drugs
- U.S. DEPARTMENT OF HOMELAND SECURITY: DHS Statement on Protecting the Nation from Foreign Terrorist Entry to the United States
- PHARMACEUTICAL CARE MANAGEMENT CARE ASSOCIATION: Federal Circuit Court Unanimously Strikes Down Arkansas Mandate Restricting PBM Tools
- PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION: Congressional Budget Office Score of Medicare Point-of-Sale Rebates Undermines Drugmakers’ Signature Issue
Innovation
- SANOFI: FDA expands indication for Soliqua® 100/33
- DIAGNOSTIC SOLUTIONS LABORATORY: Revolutionizes Precision Medicine with GenomicInsight™ Genomic Health Profile Powered by Opus23 Explorer™
- CANNABICS PHARMACEUTICALS INC.: Cannabics Pharmaceuticals and Wize Pharma to Form Joint Venture to Develop Cannabinoid Based Ophthalmic Therapeutics
- ACTINIUM PHARMACEUTICALS: Appoints Qing Liang, PhD, DABR as Vice President, Head of Radiation Sciences to Further Innovation for its AWE Technology Platform and Growing Pipeline of Antibody Radiation Conjugate Therapies
Regulatory
- SAREPTA THERAPEUTICS, INC.: Announces FDA Acceptance of Golodirsen (SRP-4053) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53
- SANOFI: FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
- MYLAN INC: Announces FDA Approval of Wixela™ Inhub™ (fluticasone propionate and salmeterol inhalation powder, USP), First Generic of ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder)
- SUNOVION PHARMACEUTICALS INC: Receives Complete Response Letter from FDA for Apomorphine Sublingual Film (APL-130277)
Alerts Sign-up